These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30122369)

  • 41. Aldose reductase inhibitors and nanodelivery of diabetic therapeutics.
    Prior AM; Thapa M; Hua DH
    Mini Rev Med Chem; 2012 Apr; 12(4):326-36. PubMed ID: 22303947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
    Wu B; Yang Y; Qin X; Zhang S; Jing C; Zhu C; Ma B
    ChemMedChem; 2013 Dec; 8(12):1913-7. PubMed ID: 24115741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aldose reductase inhibitors and diabetic kidney disease.
    Oates PJ
    Curr Opin Investig Drugs; 2010 Apr; 11(4):402-17. PubMed ID: 20336588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aldose reductase inhibitors.
    Kirchain WR; Rendell MS
    Pharmacotherapy; 1990; 10(5):326-36. PubMed ID: 2122421
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate.
    Vander Jagt DL; Kolb NS; Vander Jagt TJ; Chino J; Martinez FJ; Hunsaker LA; Royer RE
    Biochim Biophys Acta; 1995 Jun; 1249(2):117-26. PubMed ID: 7599164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors.
    Ovais S; Pushpalatha H; Reddy GB; Rathore P; Bashir R; Yaseen S; Dheyaa A; Yaseen R; Tanwar O; Akthar M; Samim M; Javed K
    Eur J Med Chem; 2014 Jun; 80():209-17. PubMed ID: 24780598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discoveries in research on diabetic keratopathy.
    Cisarik-Fredenburg P
    Optometry; 2001 Nov; 72(11):691-704. PubMed ID: 12363257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition.
    Javid N; Munir R; Chaudhry F; Imran A; Zaib S; Muzaffar A; Iqbal J
    Bioorg Chem; 2020 Jun; 99():103852. PubMed ID: 32325339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus.
    Kousaxidis A; Petrou A; Lavrentaki V; Fesatidou M; Nicolaou I; Geronikaki A
    Eur J Med Chem; 2020 Dec; 207():112742. PubMed ID: 32871344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
    Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
    Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibitory effect of ursolic acid derivatives on recombinant human aldose reductase.
    Lee EH; Popov SA; Lee JY; Shpatov AV; Kukina TP; Kang SW; Pan CH; Um BH; Jung SH
    Bioorg Khim; 2011; 37(5):637-44. PubMed ID: 22332359
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
    Yabe-Nishimura C
    Pharmacol Rev; 1998 Mar; 50(1):21-33. PubMed ID: 9549756
    [No Abstract]   [Full Text] [Related]  

  • 54. Residues affecting the catalysis and inhibition of rat lens aldose reductase.
    Carper DA; Hohman TC; Old SE
    Biochim Biophys Acta; 1995 Jan; 1246(1):67-73. PubMed ID: 7811733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Soyasaponins from Zolfino bean as aldose reductase differential inhibitors.
    Balestri F; De Leo M; Sorce C; Cappiello M; Quattrini L; Moschini R; Pineschi C; Braca A; La Motta C; Da Settimo F; Del-Corso A; Mura U
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):350-360. PubMed ID: 30734590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q; Liu Q; Ouyang D
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel synthesis of nitro-quinoxalinone derivatives as aldose reductase inhibitors.
    Hussain S; Parveen S; Qin X; Hao X; Zhang S; Chen X; Zhu C; Ma B
    Bioorg Med Chem Lett; 2014 May; 24(9):2086-9. PubMed ID: 24726808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
    Madhu SV; Verma NP; Goel A; Kapoor VK
    J Assoc Physicians India; 1992 Oct; 40(10):679-81. PubMed ID: 1307356
    [No Abstract]   [Full Text] [Related]  

  • 60. Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity.
    D'Andrea F; Sartini S; Piano I; Franceschi M; Quattrini L; Guazzelli L; Ciccone L; Orlandini E; Gargini C; La Motta C; Nencetti S
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1194-1205. PubMed ID: 32396745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.